Please login to the form below

Not currently logged in
Email:
Password:

Former Boehringer diabetes marketing VP joins Gelesis

Dr David Pass takes up the chief operating officer position

Gelesis Dr David PassGelesis, a biotech focused on the development of products to improve glycaemic control, has appointed Dr David Pass as its chief operating officer.

Dr Pass brings over 20 years of commercial expertise in the diabetes and metabolics areas among others to Gelesis, and takes on responsibility for all business development and product commercialisation, including the firm's lead candidate, Gelesis100.

Most recently, Dr Pass served as Boehringer Ingelheim's vice president of marketing for its diabetes portfolio, and led the pharma firm's alliance with Lilly & Co on mid- and late-stage diabetes compound development.

He has previously worked at Gilead Sciences as senior director of cardiovascular strategic marketing, at Johnson & Johnson as vice president of marketing for pain and institutional therapies, and as director of marketing at Bristol-Myers Squibb.

Yishai Zohar, chief executive officer of Gelesis, said: “We are excited to have David onboard as we prepare for the potential launch of our first product, Gelesis100.

“David brings invaluable commercial, strategic and business development experience across a broad range of therapeutic areas and has a proven track record of building successful franchises.”

8th September 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics